Drug Trial Radar · NCT07230730
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Jan 13, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.
Conditions
- Hyperlipidemia
Interventions
SHR-1918Drug
SHR-1918
SHR-1918 placeboDrug
SHR-1918 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage change of serum LDL-C from baselineTime frame: Baseline and Week 24
- The percentage change in serum TG from baselineTime frame: Baseline and Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.